Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 03 2023
Historique:
received: 12 08 2022
accepted: 21 03 2023
medline: 3 4 2023
entrez: 30 3 2023
pubmed: 31 3 2023
Statut: epublish

Résumé

The induction of antiviral innate immunity by systemic immunization with live virus can be employed to positively impact the response to therapeutic vaccination. We previously demonstrated that systemic immunization with a non-replicating MVA encoding CD40 ligand (CD40L) enhances innate immune cell activation and function, and triggers potent antitumor CD8

Identifiants

pubmed: 36997583
doi: 10.1038/s41598-023-32060-2
pii: 10.1038/s41598-023-32060-2
pmc: PMC10060934
doi:

Substances chimiques

CD40 Ligand 147205-72-9
Brachyury protein EQ43SC3GDB
Antibodies, Neoplasm 0
Cancer Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5162

Informations de copyright

© 2023. The Author(s).

Références

Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16606-11
pubmed: 15536127
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11513-8
pubmed: 20534518
Clin Cancer Res. 2019 Aug 15;25(16):4933-4944
pubmed: 31110074
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
J Infect Dis. 2021 Mar 29;223(6):1062-1072
pubmed: 32726422
Clin Cancer Res. 2017 Nov 15;23(22):6833-6845
pubmed: 28855356
Br J Cancer. 2006 Jan 30;94(2):259-67
pubmed: 16404427
Oncol Lett. 2021 Apr;21(4):287
pubmed: 33732363
J Exp Med. 2000 May 1;191(9):1513-24
pubmed: 10790426
EMBO J. 1995 Oct 2;14(19):4763-72
pubmed: 7588606
J Leukoc Biol. 2002 Feb;71(2):173-83
pubmed: 11818437
EMBO J. 2000 Jul 3;19(13):3159-67
pubmed: 10880430
Nat Rev Cancer. 2021 Mar;21(3):181-197
pubmed: 33462501
Clin Cancer Res. 2012 Jul 15;18(14):3868-79
pubmed: 22611028
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2140-5
pubmed: 18245380
Clin Exp Allergy. 2018 Oct;48(10):1345-1353
pubmed: 29974988
Cancer Res. 1990 Mar 1;50(5):1550-8
pubmed: 1689212
Carcinogenesis. 2020 Jul 10;41(5):551-560
pubmed: 31713604
EMBO J. 1993 Aug;12(8):3211-20
pubmed: 8344258
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Oncoimmunology. 2013 Jan 1;2(1):e23033
pubmed: 23483678
Nat Commun. 2019 Nov 6;10(1):5041
pubmed: 31695037
J Clin Invest. 2002 Oct;110(7):983-92
pubmed: 12370276
Nature. 2003 Feb 13;421(6924):756-60
pubmed: 12610629
J Clin Oncol. 2018 Mar 10;36(8):741-748
pubmed: 29244528
J Infect Dis. 2019 Jun 5;220(1):46-56
pubmed: 30796818
Oncologist. 2020 Jul;25(7):560-e1006
pubmed: 31876334
PLoS One. 2013 Aug 12;8(8):e73511
pubmed: 23951355
Sci Rep. 2021 Feb 8;11(1):3346
pubmed: 33558639
Vaccine. 2020 Mar 4;38(11):2608-2619
pubmed: 32057576
Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
pubmed: 16493418
Breast Cancer Res. 2018 Jan 30;20(1):8
pubmed: 29382369
Cancer Res. 2001 Jun 15;61(12):4744-9
pubmed: 11406546
J Immunol. 2005 Oct 15;175(8):5504-15
pubmed: 16210659
Clin Cancer Res. 2013 Nov 15;19(22):6286-95
pubmed: 23983255
Int J Cancer. 2013 Jan 1;132(1):246-7
pubmed: 22674354
Clin Exp Immunol. 2001 May;124(2):214-22
pubmed: 11422197
Immunology. 1996 Jun;88(2):289-93
pubmed: 8690463
Cancer Cell. 2004 Apr;5(4):317-28
pubmed: 15093539
Cell. 2004 Aug 6;118(3):277-9
pubmed: 15294153
Hum Mol Genet. 2005 Apr 1;14(7):885-92
pubmed: 15703190
Methods Mol Biol. 2004;269:77-100
pubmed: 15114009
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13980-5
pubmed: 16172378
J Immunother Cancer. 2021 Sep;9(9):
pubmed: 34479925
J Clin Oncol. 2007 Mar 1;25(7):876-83
pubmed: 17327609
PLoS One. 2010 Jan 13;5(1):e8668
pubmed: 20084270
Mol Cell Proteomics. 2020 Feb;19(2):390-404
pubmed: 31848261
N Engl J Med. 2019 Nov 14;381(20):1897-1908
pubmed: 31722150
PLoS One. 2010 Mar 11;5(3):e9659
pubmed: 20300179
Nat Rev Cancer. 2015 Jun;15(6):361-70
pubmed: 25998715
Vaccine. 2009 Dec 9;27(52):7442-50
pubmed: 19539582
Sci Rep. 2021 Jan 15;11(1):1563
pubmed: 33452364
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9
pubmed: 1350088
Science. 2005 Jan 28;307(5709):593-6
pubmed: 15591165
Am J Surg Pathol. 2015 Oct;39(10):1305-12
pubmed: 26099010
Pharmacol Res. 2014 Sep;87:42-59
pubmed: 24928736
Front Oncol. 2019 Nov 26;9:1308
pubmed: 31850207
Annu Rev Med. 2020 Jan 27;71:47-58
pubmed: 31412220
J Clin Invest. 2010 Feb;120(2):533-44
pubmed: 20071775
J Pathol. 2006 Jun;209(2):157-65
pubmed: 16538613
Oncogenesis. 2021 Nov 13;10(11):77
pubmed: 34775465
ISRN Oncol. 2012;2012:428062
pubmed: 23227361
Trends Immunol. 2003 Nov;24(11):603-9
pubmed: 14596885
Vaccine. 2013 Jun 24;31(29):3025-33
pubmed: 23664987
J Immunol. 1996 Oct 1;157(7):3054-64
pubmed: 8816415
J Exp Med. 2000 Feb 21;191(4):651-60
pubmed: 10684857
Cancer Res. 2005 Mar 1;65(5):1858-67
pubmed: 15753384
Chem Biol Drug Des. 2009 Sep;74(3):246-57
pubmed: 19703026
Clin Cancer Res. 2007 Apr 15;13(8):2471-8
pubmed: 17438107
Front Immunol. 2013 Aug 27;4:251
pubmed: 23986761
J Immunol. 2005 Aug 15;175(4):2152-7
pubmed: 16081781
Cancer Immunol Immunother. 2016 May;65(5):537-49
pubmed: 26961085

Auteurs

Maria Hinterberger (M)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany. mahi@bavarian-nordic.com.

Kathrin Endt (K)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

Barbara Bathke (B)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

Matthias Habjan (M)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

Alexander Heiseke (A)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
GlaxoSmithKline GmbH, Prinzregentenpl. 9, 81675, Munich, Germany.

Marc Schweneker (M)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

Julia Von Rohrscheidt (J)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Origenis GmbH, Am Klopferspitz 19A, 82152, Planegg, Germany.

Cigdem Atay (C)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

Paul Chaplin (P)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

Markus Kalla (M)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

Jürgen Hausmann (J)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

Carolin Schmittwolf (C)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

Henning Lauterbach (H)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Hookipa Pharma Inc, 350 Fifth Avenue, Room/Suite 7240, New York City, NY, USA.

Ariane Volkmann (A)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

Hubertus Hochrein (H)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.

José Medina-Echeverz (J)

Bavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Affimed, Im Neuenheimer Feld 582, 69120, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH